Abstract:Coronary atherosclerosis leads to ischaemic heart disease, the single greatest cause of death in developed countries. In the ischaemic heart, blockage of coronary circulation causes myocardial infarction (MI) which produces two types of damage: initial ischaemic injury and reperfusion injury following restoration of blood flow. Ischaemia–reperfusion (IR) injury leads to cardiac contractile dysfunction, loss of cardiomyocytes, maladaptive remodelling, and eventually congestive heart failure. Since mammalian cardiomyocytes are terminally differentiated cells with limited regenerative capacity, preservation of cardiomyocytes is an area that has attracted a lot of interest from both scientists and physicians. In this regard, studies by Kewalraman et al. 1 have defined AMP-activated protein kinase (AMPK) as a powerful cardiac protector against tumour necrosis factor-alpha (TNF-α)-triggered cardiomyocyte apoptosis through phosphorylating Bad and subsequently suppressing mitochondrial apoptotic signalling. This discovery sheds new light on our understanding of the cardiac beneficial effects of clinically used hypoglycaemic drugs such as dexamethasone and metformin (MET), which activate AMPK and are widely used to treat type II diabetes. Equally important, this study may have important clinical relevance, since excessive TNF-α production has been implicated in the pathogenesis of a multitude of metabolic as well as cardiovascular disorders, including obesity, diabetes, and ischaemic heart disease. Thus, we envision that this work would stimulate a flurry of basic and translational studies in the field of cardiovascular biology and medicine and in the area of … *Corresponding author. Tel: +1 410 558 8662; fax: +1 410 558 8150. E-mail address: xiaor{at}grc.nia.nih.gov

AMPK and TNF-alpha at the Crossroad of Cell Survival and Death in Ischaemic Heart.